Concepts (102)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 7 | 2024 | 1092 | 1.050 |
Why?
|
| Quinolines | 1 | 2024 | 78 | 0.820 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2024 | 93 | 0.800 |
Why?
|
| Receptors, Estrogen | 2 | 2024 | 183 | 0.800 |
Why?
|
| Cell Movement | 3 | 2024 | 655 | 0.670 |
Why?
|
| Cell Survival | 1 | 2024 | 945 | 0.670 |
Why?
|
| Ovarian Neoplasms | 1 | 2024 | 415 | 0.620 |
Why?
|
| Health Status Disparities | 2 | 2020 | 719 | 0.490 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 1723 | 0.490 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 760 | 0.470 |
Why?
|
| Toll-Like Receptors | 2 | 2020 | 51 | 0.470 |
Why?
|
| Immunity, Innate | 3 | 2024 | 171 | 0.410 |
Why?
|
| Patents as Topic | 1 | 2009 | 14 | 0.310 |
Why?
|
| Universities | 2 | 2020 | 559 | 0.310 |
Why?
|
| Cell Line, Tumor | 5 | 2024 | 2676 | 0.280 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2020 | 863 | 0.260 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2007 | 29 | 0.260 |
Why?
|
| Estrogen Receptor beta | 1 | 2007 | 39 | 0.260 |
Why?
|
| Estrogen Receptor alpha | 1 | 2007 | 121 | 0.240 |
Why?
|
| Genetics | 1 | 2006 | 10 | 0.240 |
Why?
|
| Estrogens | 1 | 2007 | 203 | 0.230 |
Why?
|
| Up-Regulation | 2 | 2008 | 536 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2009 | 968 | 0.220 |
Why?
|
| Benzodioxoles | 1 | 2024 | 4 | 0.220 |
Why?
|
| Cyclopentanes | 1 | 2024 | 26 | 0.210 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2024 | 44 | 0.210 |
Why?
|
| Computational Biology | 1 | 2006 | 327 | 0.200 |
Why?
|
| Curriculum | 1 | 2006 | 318 | 0.200 |
Why?
|
| Humans | 15 | 2024 | 43102 | 0.190 |
Why?
|
| Signal Transduction | 2 | 2009 | 2157 | 0.170 |
Why?
|
| Minority Groups | 2 | 2021 | 690 | 0.160 |
Why?
|
| Genetic Variation | 2 | 2019 | 430 | 0.140 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2020 | 174 | 0.140 |
Why?
|
| Neoplasms | 1 | 2009 | 1377 | 0.140 |
Why?
|
| Male | 8 | 2024 | 23409 | 0.140 |
Why?
|
| Cell Proliferation | 1 | 2024 | 1455 | 0.140 |
Why?
|
| Homeodomain Proteins | 2 | 2009 | 150 | 0.140 |
Why?
|
| Genotype | 1 | 2020 | 800 | 0.140 |
Why?
|
| Rural Population | 1 | 2020 | 373 | 0.130 |
Why?
|
| Body Size | 1 | 2017 | 49 | 0.130 |
Why?
|
| Community-Based Participatory Research | 1 | 2020 | 352 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 734 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 590 | 0.110 |
Why?
|
| Female | 5 | 2024 | 24698 | 0.110 |
Why?
|
| Health Promotion | 1 | 2020 | 704 | 0.110 |
Why?
|
| Transcription Factors | 2 | 2009 | 735 | 0.100 |
Why?
|
| Inflammation | 1 | 2019 | 758 | 0.100 |
Why?
|
| North Carolina | 2 | 2021 | 127 | 0.080 |
Why?
|
| Receptor Cross-Talk | 1 | 2009 | 18 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1285 | 0.080 |
Why?
|
| Jamaica | 2 | 2020 | 11 | 0.080 |
Why?
|
| Obesity | 1 | 2017 | 1151 | 0.070 |
Why?
|
| Receptors, Androgen | 1 | 2009 | 144 | 0.070 |
Why?
|
| United States | 1 | 2019 | 5205 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 81 | 0.070 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2007 | 19 | 0.070 |
Why?
|
| Middle Aged | 5 | 2021 | 12222 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 760 | 0.060 |
Why?
|
| Virginia | 1 | 2006 | 12 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 2853 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2008 | 1271 | 0.060 |
Why?
|
| Georgia | 1 | 2006 | 192 | 0.060 |
Why?
|
| Adult | 4 | 2021 | 13872 | 0.060 |
Why?
|
| Aged | 4 | 2020 | 8214 | 0.050 |
Why?
|
| Logistic Models | 2 | 2021 | 1009 | 0.050 |
Why?
|
| Risk Factors | 3 | 2020 | 3994 | 0.050 |
Why?
|
| Apoptosis | 1 | 2012 | 1568 | 0.050 |
Why?
|
| Internet | 1 | 2006 | 236 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 3156 | 0.050 |
Why?
|
| Adolescent | 2 | 2021 | 6081 | 0.050 |
Why?
|
| Time Factors | 1 | 2007 | 1857 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 638 | 0.040 |
Why?
|
| Students | 1 | 2006 | 626 | 0.040 |
Why?
|
| Trust | 1 | 2021 | 167 | 0.040 |
Why?
|
| Research Design | 1 | 2021 | 385 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2019 | 91 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 310 | 0.030 |
Why?
|
| Hela Cells | 1 | 2019 | 376 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 863 | 0.030 |
Why?
|
| Chemokines | 1 | 2017 | 96 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 934 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 140 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 678 | 0.030 |
Why?
|
| Entropy | 1 | 2012 | 14 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 374 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 195 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 5080 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 299 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 80 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2009 | 74 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 181 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2009 | 92 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 652 | 0.020 |
Why?
|
| Mesoderm | 1 | 2008 | 73 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2008 | 196 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 137 | 0.020 |
Why?
|
| Cadherins | 1 | 2008 | 102 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 290 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 532 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 592 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 701 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2008 | 434 | 0.010 |
Why?
|